DDInter1840 DDInter489
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Trabectedin {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Deferiprone
Trabectedin {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deferiprone
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) causes {v} (Side Effect) Multi-organ failure
Multi-organ failure {u} (Side Effect) is caused by {v} (Compound) Carfilzomib
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deferiprone
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Pentamidine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Procarbazine
Procarbazine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trabectedin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Trabectedin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) causes Multi-organ failure (Side Effect) and Multi-organ failure (Side Effect) is caused by Carfilzomib (Compound) and Carfilzomib may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Pentamidine (Compound) and Pentamidine may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Deferiprone
Trabectedin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Procarbazine (Compound) and Procarbazine may lead to a major life threatening interaction when taken with Deferiprone